Isolation of broadly reactive, tumor-specific, HLA class-I restricted CTL from blood lymphocytes of a breast cancer patient

Human Immunology

Volumn 60, Issue 12, 1999, Pages 1195-1206

  Verdegaal, Els M E ^a   Ten Bokkel Huinink, Daan ^a   Hoogstraten, Conny ^a   Marijnissen, Anne Karien ^a   Gorsira, Michael B ^b   Claas, F H J ^a   Osanto, Susanne ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Diaconesse Hospital   (Netherlands)

Author keywords

Allogeneic tumor cells; Breast cancer; Cytotoxic T lymphocytes; HLA class I antigens; Immunotherapy

Indexed keywords

CANCER VACCINE; CHROMIUM 51; DIFFERENTIATION ANTIGEN; HLA A2 ANTIGEN; HLA ANTIGEN CLASS 1; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; MONOCLONAL ANTIBODY; ONCOPROTEIN; PROTEIN P53; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; B LYMPHOCYTE; BREAST CARCINOMA; BREAST EPITHELIUM; CANCER IMMUNOTHERAPY; CELL STRAIN K 562; CELL STRAIN MCF 7; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; EPSTEIN BARR VIRUS; FEMALE; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; KIDNEY TUBULE EPITHELIUM; MELANOMA CELL; MIXED LYMPHOCYTE CULTURE; PRIORITY JOURNAL;

ANTIGENS, CD58; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CELL LINE, TRANSFORMED; EPITOPES, T-LYMPHOCYTE; FEMALE; HLA-A2 ANTIGEN; HUMANS; IMMUNOPHENOTYPING; INTERCELLULAR ADHESION MOLECULE-1; K562 CELLS; PEPTIDES; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0033398543     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0198-8859(99)00124-X     Document Type: Article

References (54)

1. Parkin D.M., Pisani P., Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer. 54:1993;594.
2. Rosenberg S.A., Packard B.S., Aebersold P.M., Solomon D., Topalian S.L., Toy S.T., Simon P., Lotze M.T., Yang J.C., Seipp C.A. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report [see comments]. N Engl J Med. 319:1988;1676.
3. Belldegrun A., Muul L.M., Rosenberg S.A. Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer isolation, characterization, and antitumor activity . Cancer Res. 48:1988;206.
4. Goedegebuure P.S., Douville L.M., Li H., Richmond G.C., Schoof D.D., Scavone M., Eberlein T.J. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma a pilot study . J Clin Oncol. 13:1995;1939.
5. Disis M.L., Calenoff E., McLaughlin G., Murphy A.E., Chen W., Groner B., Jeschke M., Lydon N., McGlynn E., Livingston R.B. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res. 54:1994;16.
6. Linehan D.C., Goedegebuure P.S., Peoples G.E., Rogers S.O., Eberlein T.J. Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer. J Immunol. 155:1995;4486.
7. Goedegebuure P.S., Douville C.C., Doherty J.M., Linehan D.C., Lee K.Y., Ganguly E.K., Eberlein T.J. Simultaneous production of T helper-1-like cytokines and cytolytic activity by tumor-specific T cells in ovarian and breast cancer. Cell Immunol. 175:1997;150.
8. Baxevanis C.N., Dedoussis G.V., Papadopoulos N.G., Missitzis I., Stathopoulos G.P., Papamichail M. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer. Cancer. 74:1994;1275.
9. Toso J.F., Oei C., Oshidari F., Tartaglia J., Paoletti E., Lyerly H.K., Talib S., Weinhold K.J. MAGE-1-specific precursor cytotoxic T-lymphocytes present among tumor-infiltrating lymphocytes from a patient with breast cancer characterization and antigen-specific activation . Cancer Res. 56:1996;16.
10. Peoples G.E., Goedegebuure P.S., Smith R., Linehan D.C., Yoshino I., Eberlein T.J. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci U S A. 92:1995;432.
11. Zaks T.Z., Rosenberg S.A. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors. Cancer Res. 58:1998;4902.
12. Dahiya R., Kwak K.S., Byrd J.C., Ho S., Yoon W.H., Kim Y.S. Mucin synthesis and secretion in various human epithelial cancer cell lines that express the MUC-1 mucin gene. Cancer Res. 53:1993;1437.
13. Brasseur F., Marchand M., Vanwijck R., Herin M., Lethe B., Chomez P., Boon T. Human gene MAGE-1, which codes for a tumor-rejection antigen, is expressed by some breast tumors [letter]. Int J Cancer. 52:1992;839.
14. De Smet C., Lurquin C., van der Bruggen P., De Plaen E., Brasseur F., Boon T. Sequence and expression pattern of the human MAGE2 gene. Immunogenetics. 39:1994;121.
15. Russo V., Traversari C., Verrecchia A., Mottolese M., Natali P.G., Bordignon C. Expression of the MAGE gene family in primary and metastatic human breast cancer implications for tumor antigen-specific immunotherapy . Int J Cancer. 64:1995;216.
16. Litvinov S.V., Velders M.P., Bakker H.A., Fleuren G.J., Warnaar S.O. Ep-CAM a human epithelial antigen is a homophilic cell-cell adhesion molecule . J Cell Biol. 125:1994;437.
17. Robbins P.F., Eggensperger D., Qi C.F., Schlom J. Definition of the expression of the human carcinoembryonic antigen and non-specific cross-reacting antigen in human breast and lung carcinomas. Int J Cancer. 53:1993;892.
18. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer correlation of relapse and survival with amplification of the HER-2/neu oncogene . Science. 235:1987;177.
19. Gnjatic S., Cai Z., Viguier M., Chouaib S., Guillet J.G., Choppin J. Accumulation of the p53 protein allows recognition by human CTL of a wild-type p53 epitope presented by breast carcinomas and melanomas. J Immunol. 160:1998;328.
20. Koelman C.A., Mulder A., Jutte N.H., Vaessen L.M., Balk A.H., Weimar W., Doxiadis I.I., Claas F.H. The application of human monoclonal antibodies for monitoring donor derived soluble HLA class I molecules in the serum of heart transplant recipients. Hum Immunol. 59:1998;106.
21. Verduyn W., Doxiadis I.I., Anholts J., Drabbels J.J., Naipal A., D'Amaro J., Persijn G.G., Giphart M.J., Schreuder G.M. Biotinylated DRB sequence-specific oligonucleotides. Comparison to serologic HLA-DR typing of organ donors in eurotransplant. Hum Immunol. 37:1993;59.
22. Herin M., Lemoine C., Weynants P., Vessiere F., Van Pel A., Knuth A., Devos R., Boon T. Production of stable cytolytic T-cell clones directed against autologous human melanoma. Int J Cancer. 39:1987;390.
23. Brouwenstijn N., Gaugler B., Kruse K.M., van der Spek C.W., Mulder A., Osanto S., van den Eynde B.J., Schrier P.I. Renal-cell carcinoma-specific lysis by cytotoxic T-lymphocyte clones isolated from peripheral blood lymphocytes and tumor-infiltrating lymphocytes. Int J Cancer. 68:1996;177.
24. Espevik T., Nissen-Meyer J. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J Immunol Methods. 95:1986;99.
25. Parham P., Barnstable C.J., Bodmer W.F. Use of a monoclonal antibody (W6/32) in structural studies of HLA-A,B,C, antigens. J Immunol. 123:1979;342.
26. McMichael A.J., Parham P., Rust N., Brodsky F. A monoclonal antibody that recognizes an antigenic determinant shared by HLA A2 and B17. Hum Immunol. 1:1980;121.
27. Rebai N., Malissen B. Structural and genetic analyses of HLA class I molecules using monoclonal xenoantibodies. Tissue Antigens. 22:1983;107.
28. Yang J.C., Topalian S.L., Schwartzentruber D.J., Parkinson D.R., Marincola F.M., Weber J.S., Seipp C.A., White D.E., Rosenberg S.A. The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. A phase I study and a randomized prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL-2. Cancer. 76:1995;687.
29. van de Vijver M.J., Peterse J.L., Mooi W.J., Wisman P., Lomans J., Dalesio O., Nusse R. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med. 319:1988;1239.
30. Wesseling J., van der Valk S.W., Vos H.L., Sonnenberg A., Hilkens J. Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J Cell Biol. 129:1995;255.
31. de Boer M., Parren P., Dove J., Ossendorp F., van der Horst G., Reeder J. Functional characterization of a novel anti-B7 monoclonal antibody. Eur J Immunol. 22:1992;3071.
32. Nozawa Y., Wachi E., Tominaga K., Abe M., Wakasa H. A novel monoclonal antibody (FUN-1) identifies an activation antigen in cells of the B-cell lineage and Reed-Sternberg cells. J Pathol. 169:1993;309.
33. Guilloux Y., Lucas S., Brichard V.G., Van Pel A., Viret C., De Plaen E., Brasseur F., Lethe B., Jotereau F., Boon T. A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene. J Exp Med. 183:1996;1173.
34. van Elsas A., Aarnoudse C., van der Minne C.E., van der Spek C.W., Brouwenstijn N., Osanto S., Schrier P.I. Transfection of IL-2 augments CTL response to human melanoma cells in vitro immunological characterization of a melanoma vaccine . J Immunother. 20:1997;343.
35. Bernhard H., Karbach J., Wolfel T., Busch P., Storkel S., Stockle M., Wolfel C., Seliger B., Huber C., Meyer zum Buschenfelde K.H. Cellular immune response to human renal-cell carcinomas definition of a common antigen recognized by HLA-A2-restricted cytotoxic T-lymphocyte (CTL) clones . Int J Cancer. 59:1994;837.
36. Disis M.L., Smith J.W., Murphy A.E., Chen W., Cheever M.A. In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein. Cancer Res. 54:1994;1071.
37. Fisk B., Blevins T.L., Wharton J.T., Ioannides C.G. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med. 181:1995;2109.
38. Apostolopoulos V., Karanikas V., Haurum J.S., McKenzie I.F. Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen. J Immunol. 159:1997;5211.
39. Ropke M., Regner M., Claesson M.H. T cell-mediated cytotoxicity against p53-protein derived peptides in bulk and limiting dilution cultures of healthy donors. Scand J Immunol. 42:1995;98.
40. Ropke M., Hald J., Guldberg P., Zeuthen J., Norgaard L., Fugger L., Svejgaard A., Van der Burg S., Nijman H.W., Melief C.J., Claesson M.H. Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. Proc Natl Acad Sci U S A. 93:1996;14704.
41. Ras E., van der Burg S.H., Zegveld S.T., Brandt R.M., Kuppen P.J., Offringa R., Warnaar S.O., van de Velde C.J., Melief C.J. Identification of potential HLA-A *0201 restricted CTL epitopes derived from the epithelial cell adhesion molecule (Ep-CAM) and the carcinoembryonic antigen (CEA). Hum Immunol. 53:1997;81.
42. Gotch F., Rothbard J., Howland K., Townsend A., McMichael A. Cytotoxic T lymphocytes recognize a fragment of influenza virus matrix protein in association with HLA-A2. Nature. 326:1987;881.
43. Pericle F., Epling-Burnette P.K., Podack E.R., Wei S., Djeu J.Y. CD40-CD40L interactions provide "third-party" costimulation for T cell response against B7-1-transfected human breast tumor cells. J Leukoc Biol. 61:1997;201.
44. Wolfel T., Herr W., Coulie P., Schmitt U., Meyer zum Buschenfelde K.H., Knuth A. Lysis of human pancreatic adenocarcinoma cells by autologous HLA-class I-restricted cytolytic T-lymphocyte (CTL) clones. Int J Cancer. 54:1993;636.
45. Shinde S., Wu Y., Guo Y., Niu Q., Xu J., Grewal I.S., Flavell R., Liu Y. CD40L is important for induction of, but not response to, costimulatory activity ICAM-1 as the second costimulatory molecule rapidly up-regulated by CD40L . J Immunol. 157:1996;2764.
46. + T cells. J Immunol. 158:1997;637.
47. Motta I., Lone Y.C., Kourilsky P. In vitro induction of naive cytotoxic T lymphocytes with complexes of peptide and recombinant MHC class I molecules coated onto beads role of TCR/ligand density . Eur J Immunol. 28:1998;3685.
48. Rivoltini L., Barracchini K.C., Viggiano V., Kawakami Y., Smith A., Mixon, Restifo N.P., Topalian S.L., Simonis T.B., Rosenberg S.A. Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes. Cancer Res. 55:1995;3149.
49. Benham A.M., Neefjes J.J. Proteasome activity limits the assembly of MHC class I molecules after IFN-gamma stimulation. J Immunol. 159:1997;5896.
50. Crowley N.J., Slingluff C.L.J., Darrow T.L., Seigler H.F. Generation of human autologous melanoma-specific cytotoxic T-cells using HLA-A2-matched allogeneic melanomas. Cancer Res. 50:1990;492.
51. Kawakami Y., Robbins P.F., Wang X., Tupesis J.P., Parkhurst M.R., Kang X., Sakaguchi K., Appella E., Rosenberg S.A. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles. J Immunol. 161:1998;6985.
52. Kawakami Y., Eliyahu S., Jennings C., Sakaguchi K., Kang X., Southwood S., Robbins P.F., Sette A., Appella E., Rosenberg S.A. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol. 154:1995;3961.
53. Bakker A.B., Schreurs M.W., de Boer A.J., Kawakami Y., Rosenberg S.A., Adema G.J., Figdor C.G. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med. 179:1994;1005.
54. Reddish M.A., MacLean G.D., Rao Koganty R., Kan-Mitchell J., Jones V., Mitchell M.S., Longenecker B.M. Anti-Muc-1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic Muc-1 peptide. Int J Cancer. 76:1998;817.